How much revenue does Suzhou Zelgen Biopharmaceuticals make?

Suzhou Zelgen Biopharmaceuticals reported 532.95 million CNY in revenue for fiscal year 2024, up 37.9% from 386.44 million CNY in fiscal year 2023. In Q2 2025 revenue was 208.01 million CNY.

Where does Suzhou Zelgen Biopharmaceuticals make most of its revenue?

China: 99% of revenue by region in fiscal year 2025, followed by Overseas (1%).

What companies are similar to Suzhou Zelgen Biopharmaceuticals?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS), Junshi BIO (688180.SS), Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS), Betta Pharmaceuticals Co., Ltd. (300558.SZ).

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS) Stock

About Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tosylate tablets for liver cancer, hepatocellular carcinoma, and metastatic radioactive iodine-refractory differentiated thyroid cancer; and recombinant human thrombin for h...

At a glance

Suzhou Zelgen Biopharmaceuticals reported revenue of 532.95 million CNY for fiscal year 2024, up 37.9% from fiscal year 2023, and net income of -137.83 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 208.01 million CNY, up 57.0% from a year before. China was its largest region in fiscal year 2025, with 99% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.